The comparison between Retatrutide, semaglutide and tirzepatide is arguably the most important clinical question in metabolic peptide research right now. Here is a clear, data-driven breakdown of how they differ — in mechanism, efficacy and UK availability.

Mechanism of Action: Key Differences

• Semaglutide (Ozempic/Wegovy): GLP-1 receptor agonist only. Single receptor target.
• Tirzepatide (Mounjaro): GLP-1 + GIP dual agonist. The addition of GIP improved outcomes over semaglutide.
• Retatrutide: GLP-1 + GIP + Glucagon triple agonist. The glucagon receptor addition uniquely increases metabolic rate and fat oxidation, creating synergistic effects beyond the dual-agonist approach.

Weight Loss Efficacy: Trial Data Comparison

• Semaglutide 2.4mg (STEP 1, 68 weeks): 14.9% mean body weight reduction
• Tirzepatide 15mg (SURMOUNT-1, 72 weeks): 20.9% mean body weight reduction
• Retatrutide 12mg (Phase 2, 48 weeks): 22.5% mean body weight reduction — in a shorter timeframe

Retatrutide achieved greater weight loss at 48 weeks than tirzepatide achieved at 72 weeks — making it the most efficacious compound in the current clinical pipeline by available data.

Side Effect Profiles

All three compounds share a broadly similar GLP-1-class gastrointestinal adverse event profile — nausea, vomiting, diarrhoea and constipation, predominantly during dose escalation. Retatrutide’s additional glucagon agonism introduces some increase in heart rate, which was observed in Phase 2 data and will be monitored carefully in Phase 3.

UK Availability in 2026

• Semaglutide: MHRA-licensed (Ozempic for diabetes, Wegovy for obesity)
• Tirzepatide: MHRA-licensed (Mounjaro for diabetes and obesity)
• Retatrutide: Phase 3 trials underway; available as R&D compound from Alluvi Healthcare at alluvistore.co.uk

Which Compound for Research?

For researchers interested in the cutting edge of triple-agonist peptide science, Retatrutide’s superior Phase 2 efficacy data makes it the most compelling R&D compound currently available. The Alluvi Retatrutide 40mg pen provides the most practical high-dose research format in the UK market.